Enfortumab vedotin
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Bladder Neoplasms
Conditions
Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Trial Timeline
Dec 7, 2021 → Sep 22, 2025
NCT ID
NCT05014139About Enfortumab vedotin
Enfortumab vedotin is a phase 1 stage product being developed by Astellas Pharma for Urinary Bladder Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT05014139. Target conditions include Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07139977 | Phase 2 | Recruiting |
| NCT07347314 | Phase 2 | Recruiting |
| NCT06862219 | Approved | Recruiting |
| NCT06891560 | Phase 2 | Recruiting |
| NCT06553885 | Phase 2 | Recruiting |
| NCT06394570 | Phase 1/2 | Recruiting |
| NCT06011954 | Pre-clinical | Recruiting |
| NCT05868265 | Phase 2 | Recruiting |
| NCT04754191 | Phase 2 | Active |
| NCT05014139 | Phase 1 | Terminated |
| NCT04995419 | Phase 2 | Completed |
| NCT03219333 | Phase 2 | Completed |
| NCT03070990 | Phase 1 | Completed |
| NCT02091999 | Phase 1 | Completed |
Competing Products
20 competing products in Urinary Bladder Neoplasms